| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Nicola Valeri | Q56704921 |
| Andrea Lampis | Q58393870 | ||
| P2093 | author name string | Rodolfo Passalacqua | |
| Jens C Hahne | |||
| Margherita Ratti | |||
| P2860 | cites work | Modulation of mismatch repair and genomic stability by miR-155 | Q24612859 |
| Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer | Q24614511 | ||
| MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2) | Q24630209 | ||
| Cancer immunotherapy: the beginning of the end of cancer? | Q26752277 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| PI3K mutations in breast cancer: prognostic and therapeutic implications | Q28081992 | ||
| Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
| Origin of microsatellite instability in gastric cancer | Q30444930 | ||
| Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). | Q33813216 | ||
| Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma | Q34430572 | ||
| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. | Q34557699 | ||
| The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints | Q34943776 | ||
| Microsatellite instability is associated with the clinicopathologic features of gastric cancer in sporadic gastric cancer patients | Q35481226 | ||
| Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers | Q35790190 | ||
| Detection of microsatellite instability by fluorescence multiplex polymerase chain reaction | Q35869219 | ||
| Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. | Q36187672 | ||
| Molecular pathogenesis of sporadic duodenal cancer | Q36291749 | ||
| Detection of microsatellite instability in colorectal cancer using an alternative multiplex assay of quasi-monomorphic mononucleotide markers. | Q36485346 | ||
| Patterns of genomic instability in gastric cancer: clinical implications and perspectives | Q36499657 | ||
| Microsatellite instability status in gastric cancer: a reappraisal of its clinical significance and relationship with mucin phenotypes | Q36660380 | ||
| Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts | Q36824964 | ||
| Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening | Q37066133 | ||
| Clinicopathologic Characteristics of Microsatellite Instable Gastric Carcinomas Revisited: Urgent Need for Standardization | Q37488484 | ||
| Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis. | Q38204955 | ||
| Microsatellite instability: an update | Q38363519 | ||
| Screening for Lynch syndrome among patients with newly diagnosed endometrial cancer: a comprehensive review | Q38556281 | ||
| Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. | Q38659483 | ||
| Microsatellite Instability as a Biomarker for PD-1 Blockade | Q38735093 | ||
| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. | Q38798543 | ||
| Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial | Q38829062 | ||
| Cancer Statistics, 2017. | Q39038674 | ||
| The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing | Q39426336 | ||
| Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma | Q40071292 | ||
| Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability | Q40503160 | ||
| Classification and characterization of microsatellite instability across 18 cancer types | Q40505485 | ||
| Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy. | Q40735960 | ||
| Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. | Q41038524 | ||
| The role of DNA mismatch repair in platinum drug resistance | Q41155820 | ||
| The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses. | Q41539583 | ||
| Microsatellite instability and p53 mutations in hepatocellular carcinoma. | Q42997151 | ||
| Correlation of microsatellite instability at multiple loci with long-term survival in advanced gastric carcinoma. | Q43290553 | ||
| Microsatellite instability in gastric carcinoma with special references to histopathology and cancer stages. | Q43774673 | ||
| Microsatellite instability mutator phenotype in hepatocellular carcinoma in non-alcoholic and non-virally infected normal livers. | Q44680926 | ||
| Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival | Q46623690 | ||
| The Role of Microsatellite Instability in Positive Margin Gastric Cancer Patients | Q47206757 | ||
| Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. | Q47584566 | ||
| Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. | Q47593232 | ||
| Hypermutation and microsatellite instability in gastrointestinal cancers | Q47655313 | ||
| Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Q47745009 | ||
| Microsatellite instability in colorectal carcinoma. The comparison of immunohistochemistry and molecular biology suggests a role for hMSH6 [correction of hMLH6] immunostaining | Q47920600 | ||
| Microsatellite instability is associated with a better prognosis for gastric cancer patients after curative surgery | Q48667067 | ||
| Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. | Q50049563 | ||
| Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. | Q50331121 | ||
| Risk factors for ovarian cancers with and without microsatellite instability. | Q50695476 | ||
| Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. | Q51417165 | ||
| Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. | Q51442155 | ||
| Clinicopathologic and molecular profiles of microsatellite unstable Barrett Esophagus-associated adenocarcinoma. | Q51489470 | ||
| Oncogenic mutations in gastric cancer with microsatellite instability. | Q51538176 | ||
| MSI phenotype and MMR alterations in familial and sporadic gastric cancer. | Q51561153 | ||
| Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions. | Q51791931 | ||
| Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. | Q51814746 | ||
| Genetic aspects of gastric cancer instability. | Q53270206 | ||
| Age-related hypermethylation of the hMLH1 promoter in gastric cancers. | Q53394927 | ||
| Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. | Q54279287 | ||
| Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. | Q54533537 | ||
| Frequency of Microsatellite Instability in Unselected Sebaceous Gland Neoplasias and Hyperplasias | Q57648706 | ||
| Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability | Q57978015 | ||
| Identification in Daily Practice of Patients With Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer): Revised Bethesda Guidelines-Based ApproachVersusMolecular Screening | Q58408232 | ||
| Microsatellite Instability and Epigenetic Inactivation ofMLH1and Outcome of Patients With Endometrial Carcinomas of the Endometrioid Type | Q60369064 | ||
| Microsatellite instability in multiple gastric cancers | Q72016417 | ||
| Microsatellite instability in gallbladder carcinoma: two independent genetic pathways of gallbladder carcinogenesis | Q73152383 | ||
| Evaluation of adult papillary thyroid carcinomas by comparative genomic hybridization and microsatellite instability analysis | Q74485446 | ||
| Microsatellite instability is a genetic marker for the development of multiple gastric cancers | Q74826234 | ||
| Cancers of the papilla of vater: mutator phenotype is associated with good prognosis | Q77553516 | ||
| Genomic instability measurement in the diagnosis of thyroid neoplasms | Q77759753 | ||
| Re: Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability | Q80563869 | ||
| Mismatch repair proteins expression and microsatellite instability in skin lesions with sebaceous differentiation: a study in different clinical subgroups with and without extracutaneous cancer | Q80712537 | ||
| DNA mismatch repair deficiency in ampullary carcinoma: a morphologic and immunohistochemical study of 54 cases | Q84068763 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | molecular biology | Q7202 |
| microsatellite | Q265193 | ||
| molecular medicine | Q3523816 | ||
| pharmacology | Q128406 | ||
| stomach neoplasm | Q4335552 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 4151-4162 | |
| P577 | publication date | 2018-09-01 | |
| 2018-11-01 | |||
| P1433 | published in | Cellular and Molecular Life Sciences | Q5058352 |
| P1476 | title | Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches | |
| P478 | volume | 75 |
| Q64359351 | Conserved microsatellites may contribute to stem-loop structures in 5', 3' terminals of Ebolavirus genomes |
| Q90148001 | Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting |
| Q94571950 | Differential microRNA expression profiles associated with microsatellite status reveal possible epigenetic regulation of microsatellite instability in gastric adenocarcinoma |
| Q93175115 | Dissection of gastric cancer heterogeneity for precision oncology |
| Q98158922 | Molecular Mechanisms Contributing Bacterial Infections to the Incidence of Various Types of Cancer |
| Q92384079 | Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer |
| Q96952874 | The Anti-Tumor Effect of Nab-Paclitaxel Proven by Patient-Derived Organoids |
| Q98564973 | Understanding genomics and the immune environment of penile cancer to improve therapy |
| Q92648749 | Upregulated RACK1 attenuates gastric cancer cell growth and epithelial-mesenchymal transition via suppressing Wnt/β-catenin signaling |
Search more.